Half-year report january - june 2001

HALF-YEAR REPORT JANUARY - JUNE 2001 ·Biacore continued the positive sales trend seen in the first quarter of the year. Sales increased by 30% in the second quarter. For the first half-year 2001, sales increased by 37%. ·Pursuing its aggressive growth strategy, Biacore has continued to invest in commercializing its unique SPR array chip technology (SEK 8.0 million in the second quarter, SEK 30 million planned for the full-year 2001) and in marketing activities for the first of the new high-performance systems, Biacore®S51, which will be launched in the current quarter. As a result of these investments, earnings per share for the second quarter declined by 41% to SEK 0.40. Earnings per share for the first half-year 2001 increased by 14% to SEK 2.30. ·Biacore's collaboration with Boehringer Ingelheim Pharma KG has led to a new SPR system for manufacturing quality control applications. This new system will further extend Biacore's product offering to the pharmaceutical industry. ·Biacore has concluded a review of the economic conditions in its major markets and maintains its forecast and expects sales for the full-year 2001 to increase by more than 20%, with substantial quarterly variations. January - June Change April June Change - 2001 2000 2001 2000 Sales, SEK million 254.9 185.4 37% 122.4 94.4 30% Operating income, 29.2 25.6 14% 3.4 8.5 -60% SEK million Operating margin, % 11 14 3 9 Income after financial items, SEK million 34.0 28.7 18% 6.0 9.7 -38% Earnings per share, 2.30 2.02 14% 0.40 0.68 -41% SEK Biacore is the global market leader in Surface Plasmon Resonance (SPR) based biosensor technology with its own operations in the U.S., across Europe, Japan, Australia and New Zealand. A strong patent portfolio protects Biacore's technology. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as its prime area for future growth. Based in Uppsala, Sweden, the Company is listed on the Stockholm Stock Exchange and Nasdaq in the U.S. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/07/23/20010723BIT00180/bit0001.doc The full report http://www.waymaker.net/bitonline/2001/07/23/20010723BIT00180/bit0001.pdf The full report

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com